Nordic Nanovector was established in 2009 and has its main office and laboratories in Oslo, Norway. The Company aspires to become a leading provider of Antibody-Radionuclide-Conjugate (“ARC”) clinical solutions, to address major unmet medical needs and to advance cancer care through its innovative therapy programs and patented technologies. The Company intends to directly commercialize its product candidates, by creating a differentiated and specific positioning and investing in cross-specialty collaboration and medical education. The Company is also committed to continue developing the ARC pipeline, leveraging on its proprietary nanovector targeting technology.

The Company’s lead product candidate, Betalutin™, is an Antibody-Radionuclide-Conjugate that aims to prolong the survival and improve the quality of life of patients who suffer from non-Hodgkin Lymphoma (“NHL”), a life-threatening blood cancer with a high unmet medical need. The product candidate is currently undergoing a Phase I/II clinical trial for treatment of relapsed NHL.